Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066642 | 0.77 | PDE4A (0.35) | ERCC5KLKB1 | |
| SCHEMBL876570 | 0.77 | KLKB1 (0.33) | ERCC5KLKB1 | |
| SCHEMBL9934111 | 0.77 | ERCC5 (0.35) | ERCC5KLKB1 | |
| SCHEMBL18209511 | 0.74 | HRH1 (0.40) | ERCC5KLKB1 | |
| SCHEMBL9569919 | 0.74 | ERCC5 (0.34) | ERCC5KLKB1 | |
| SCHEMBL2066942 | 0.74 | CDK2 (0.35) | ERCC5 | |
| SCHEMBL2590206 | 0.73 | RBP4 (0.30) | — | |
| SCHEMBL9968611 | 0.72 | PDE4A (0.33) | ERCC5KLKB1 | |
| SCHEMBL21368088 | 0.72 | KDM4E (0.47) | ERCC5KLKB1 | |
| SCHEMBL30224182 | 0.72 | KDM4E (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331546-B1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-12-22 | — | — | US | disclosed |
| EP-2331546-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | Sanofi-aventis (FR) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010018327-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | WO | disclosed |
| US-4569934-A | ANTIANXIETY AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | NR3C1, CNKSR1, NR3C2 | ERCC5 1397/4885KLKB1 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.